Experts now recommend eradicating all Helicobacter pylori infections unless there are compelling reasons not to. As with other infectious diseases, effective therapy should be based on susceptibility.
This blog is for clinicians as it contains substantial treatment information.
Here is the link to the full paper - titled,
Helicobacter pylori infection is an infectious disease and should be treated like one, with due consideration of antibiotic resistance and stewardship.1–4
This was the consensus of the 2015 Kyoto H pylori conference,2 and it signaled a fundamental shift in thinking. Up to now, H pylori treatment has not been based on infectious disease principles, leading to suboptimal results and antibiotic resistance. In addition, the conference recommended that H pylori infection be treated whenever it is found unless there are compelling reasons not to.
Here we review current and possible future regimens for eradicating H pylori that we hope will be more effective and will lead to less resistance than in the past.
H. Pylori as and Infectious Disease
Not until the late 1980s was H pylori recognized as the cause of peptic ulcer disease, which until then accounted for hundreds of thousands of hospitalizations and more than 100,000 surgical procedures each year.5 Now, peptic ulcer disease is routinely treated by eradicating H pylori. In addition, the World Health Organization has recommended considering H pylori eradication to reduce the risk of gastric cancer,6 which causes 738,000 deaths worldwide per year.7
The problems of how to diagnose and treat H pylori infection were taken on by gastroenterologists, and not by specialists in infectious disease.1 Even now, almost all the major reviews and consensus statements on H pylori come from gastroenterologists and are published in gastroenterology journals.2,8,9
But infectious diseases differ from most gastrointestinal diseases. In gastrointestinal problems such as constipation or inflammatory bowel disease,10 the causes are generally unknown, and there is a large placebo response to therapy. In contrast, in infectious diseases, the cause is generally known, there is no placebo response, and treatment success depends on susceptibility of the organism. Failure of proven regimens is generally due to resistant organisms, poor adherence, or, in the case of H pylori, poorly designed regimens in terms of doses, frequency of administration, or duration of therapy.
The differences extend to clinical trials of treatment.3 In other infectious diseases, treatment is based on susceptibility. The usual comparative approach in infectious diseases is a noninferiority trial in which the new treatment is compared with standard care, ie, a regimen that reliably achieves nearly 100% cure rates. Not so with H pylori. Most trials of H pylori therapy compared regimens in populations with high but unknown prevalences of resistance and therefore are of limited or no help to the clinician in choosing the best regimen for an individual patient.3
Many thousands of H pylori-infected patients participated in clinical trials in which the results would have been predictable if the researchers had assessed susceptibility before giving the drugs.11–13 Worse, many patients were also randomized to receive regimens that the investigators knew provided poor cure rates in the population being studied. This knowledge was generally not shared with the patients. This approach was used to demonstrate that a new regimen was superior to an old one, even though the new one was already known to be less affected by resistance to the key element in the comparator.
Clinicians generally do not test for susceptibility when treating H pylori, one reason being that such testing is often unavailable.3 However, almost every hospital, clinic, and major laboratory in the world provides susceptibility testing for other common local pathogens. H pylori is easy to grow, and laboratories could test for susceptibility if we asked them to.
Current H pylori recommendations may also contribute to the global increase in antimicrobal resistance.
As discussed below, all recent guidelines have recommended 4-drug non-bismuth-containing concomitant therapy as first-line therapy. An infectious disease colleague described it as a “hope therapy” because the prescriber hoped that the infection would be susceptible to either metronidazole or clarithromycin. All who receive this combination receive an antibiotic they do not need. This is an expedient rather than a medically rational choice resulting from failure to deal with H pylori as an infectious disease.
H PYLORI THERAPIES
Conceptually, treating infectious disease is straightforward: one should prescribe antimicrobial drugs to which the organism is susceptible3 (Table 1). However, clinical success lies in the details, which include the doses, frequency of doses, duration of therapy, timing of doses in relation to meals, and use of adjuvants such as antisecretory drugs, antacids, and probiotics. A number of regimens reliably yield high cure rates—95% or higher—if the organism is susceptible and the patients are adherent.
The effectiveness of any regimen may vary depending on the population it is used in, due to polymorphisms in drug-metabolizing enzymes such as CYP2C19.
Sequential therapy is obsolete
Sequential therapy for H pylori infection consisted of amoxicillin plus a proton pump inhibitor for 7 days, followed by clarithromycin, tinidazole, or metronidazole plus a proton pump inhibitor for a further 7 days. This regimen should not be used any more because concomitant therapy will always be superior (see below).
Need for 14 days of therapy
H pylori occupies a number of different niches in the body ranging from gastric mucus (which is technically outside the body) to inside gastric epithelial cells. As a general rule, 14-day therapy provides the best results, in part because the longer duration helps kill the organisms that persist in different niches.14,15
In addition, proton pump inhibitors, which are part of all the currently recommended regimens, require 3 or more days to reach their full antisecretory effectiveness, which further limits the effectiveness of short-duration therapies.
Shorter regimens should be used only if they are proved to be as good as 14-day regimens and if both achieve 95% or greater cure rates with susceptible infections.
How to choose a therapy
Since rational infectious-disease therapy is based on susceptibility, one should start by considering the susceptibility pattern in the local population and, therefore, the likely susceptibility in the patient in front of us.
Unfortunately, we do not yet have local or regional susceptibility data on H pylori for most locales. Until those data are available, we must use the indirect information that is available, such as the patient’s history of antibiotic use.
Triple therapy should not be used empirically
Triple therapy (Table 1) consists of the combination of:
Clarithromycin or metronidazole or a fluoroquinolone
Amoxicillin
A proton pump inhibitor.
However, prior use of a macrolide (eg, erythromycin, clarithromycin, or azithromycin), metronidazole, or a fluoroquinolone (eg, ciprofloxacin, levofloxacin) almost guarantees resistance to those drugs. In the United States, resistance to clarithromycin, metronidazole, levofloxacin, and related drugs is already wide- spread, and none should be used empirically in triple therapies. In contrast, amoxicillin, tetracycline, and furazolidone can often be used again, as resistance to them is rare even with prior use.
For example, 14 days of clarithromycin triple therapy (clarithromycin, amoxicillin, and a proton pump inhibitor) can be expected to cure more than 95% of patients who have susceptible infections and about 20% of those with resistant infections.16 This 20% is due to the proton pump inhibitor and amoxicillin, as the contribution to the cure rate from clarithromycin is close to zero.
If the prevalence of resistance to clarithromycin is 25%, the cure rate in the entire population will be a little more than 75%—97% in the 75% of the population with susceptible infections and 20% in patients who previously received clarithromycin (Figure 1).
If we know that our patient has an infection that is susceptible to clarithromycin, metronidazole, or levofloxacin, good results could be achieved with triple therapy that includes a proton pump inhibitor, for 14 days. Fluoroquinolones have a number of black-box warnings from the US Food and Drug Administration (www.fda.gov/Drugs/DrugSafety/ucm500143.htm) and should always be a last choice. However, in the United States, lacking definite data about susceptibility to clarithromycin, metronidazole, and levofloxacin, we should assume resistance is present and use a 4-drug regimen (eg, concomitant therapy or bismuth quadruple therapy).
Concomitant therapy is preferred
Concomitant therapy is the combination of:
Amoxicillin
Metronidazole
Clarithromycin
A proton pump inhibitor.
Functionally, this is a combination of clarithromycin and metronidazole triple therapies, given simultaneously.17 The premise is that even though the prevalence of metronidazole resistance in the United States is high (20%-40%), and so is the prevalence of clarithromycin resistance (about 20%), the prevalence of resistance to both drugs at the same time is expected to be low (eg, 0.4 × 0.2 = 0.08, or 8%) unless the drugs had previously been used together, as in some older regimens that contained both. Thus, the metronidazole will kill the clarithromycin-resistant but metronidazole-susceptible strains, and the clarithromycin will kill the clarithromycin-susceptible, metronidazole-resistant strains. Only with dual resistant strains will this regimen fail (with a 20% cure rate due to the proton pump inhibitor and amoxicillin and a population cure rate of slightly more than 90%).
The downside of this highly recommended therapy is that all who receive it are getting an antibiotic that they don’t need, which is, in a global sense, inappropriate. In other words, all those who are cured by clarithromycin also receive metronidazole, which plays no role in treatment success, and those cured by metronidazole receive unneeded clarithromycin (Figure 2). Had susceptibility testing been available, those with susceptible strains would have received appropriate triple therapies, and those with dual resistance would not have received either antibiotic.
Thus, while we recommend concomitant therapy as an empiric regimen in populations that do not have high levels of resistance to metronidazole or clarithromycin (as those would also have a high prevalence of dual resistance), one must be aware of the “dirty little secret” of inappropriate antibiotic use that accompanies it and some other H pylori therapies (eg, vonoprazan triple therapy in Japan).18–20
Bismuth quadruple therapy is an alternative
Bismuth quadruple therapy (Table 1) consists of:
Bismuth
Tetracycline
Metronidazole
A proton pump inhibitor.
This was the first truly effective regimen for H pylori. Its advantage is that it can partially or completely overcome metronidazole resistance.21,22 As such, it is potentially ideal, as it should be effective despite resistance to clarithromycin, metronidazole, or levofloxacin, and it can be used in patients allergic to penicillin.
The major downside is a high frequency of side effects, particularly abdominal pain, nausea, and vomiting, often resulting in poor adherence. Most regimens that contain antibiotics have side effects, but adherence seems to be more of a problem with bismuth quadruple therapy, probably because of the combination of the high doses of metronidazole and tetra- cycline.22 In our experience, this regimen can be effective if the physician takes the time to explain to the patient that side effects are common but treatment success depends on completing the full course of 14 days.
Another problem is that tetracycline has become difficult to obtain in many areas, and doxycycline cannot be substituted in those with metronidazole resistance. To date, it has been difficult or impossible to obtain the same excellent results with doxycycline as can be obtained with tetracycline. It is not clear why.21
To use bismuth quadruple therapy one must often use a name-brand product, Pylera. Pylera is packaged as a 10-day course, which is effective against metronidazole-susceptible infections. However, 14 days are generally required to achieve a high cure rate with metronidazole-resistant infections, which are the main indication for use of this product. Moreover, Pylera does not include a proton pump inhibitor, which must be prescribed separately.
In the United States, Pylera is expensive, costing $740 to $790 with a coupon for a 10- day supply and proportionally more for the required 14-day supply (www.goodrx.com/pylera?drug-name=pylera), whereas in Europe it costs less than 70 Euros ($73).21 If generic tetracycline is available, the US cost for 14 days of generic bismuth quadruple therapy is less than $50.
An alternate and simpler approach is to substitute amoxicillin for tetracycline.23 This regimen has been used successfully in China and was shown to be noninferior to the tetracycline-containing regimen in a head-to-head comparison.24
Recent studies have confirmed earlier Italian studies suggesting that twice-a-day bismuth and tetracycline is effective, which would further simplify therapy and possibly reduce side effects.21,23,24 These variations on bismuth quadruple therapy have not yet been optimized to where one can reliably achieve 95% or greater cure rates, and further studies are needed.
Why include more than 1 antibiotic?
The H pylori load in the stomach is typically large, which increases the odds that a sub-population of resistant organisms is present. Resistance may be due to a relatively high rate of mutation in certain bacterial genes.25 This is particularly a problem with clarithromycin, metronidazole, and fluoroquinolones and is reflected in a high rate of resistance among patients for whom single-drug regimens have failed. These drugs are always given with a second antimicrobial to which H pylori rarely becomes resistant, such as amoxicillin or tetracycline.
Why include a proton pump inhibitor?
An antisecretory drug is needed to increase the gastric pH, which makes antimicrobial therapy more effective. It also decreases antibiotic washout from the stomach and likely protects and increases the gastric concentration of some antibiotics.
The activities of amoxicillin, fluoroquinolones, and to a lesser degree clarithromycin are pH-dependent. For example, keeping the gastric pH above 6.0 promotes H pylori replication,26,27 making it is more susceptible to amoxicillin (reviewed in detail by Dore et al21). A gastric pH of 6.0 or more is very difficult to achieve with proton pump inhibitors, and has been accomplished regularly only in people who metabolize these drugs slowly (“slow metabolizers”) who received both the proton pump inhibitor and amoxicillin every 6 hours for 14 days.21
With standard clarithromycin, metronidazole, or fluoroquinolone triple therapy, proton pump inhibitors appear to provide satisfactory cure rates when given for 14 days in standard doses. However, double doses (eg, 40 mg of omeprazole or an equivalent) may be slightly better, especially in the presence of resistance.
The cure rate reflects the sum of the 2 populations of organisms: the susceptible and the resistant. In triple therapy, increasing the gastric pH with a proton pump inhibitor makes the amoxicillin component of the regimen more effective against resistant organisms and thus increases the cure rate. For example, in Western countries, esomeprazole 40 mg (approximately equivalent to rabeprazole 40 mg, omeprazole or lansoprazole 60 mg, or pantoprazole 240 mg)28 given twice a day in a 14-day triple therapy regimen cures about 40% to 50% of resistant infections. This benefit will be evident in an improvement in cure rates in populations in which resistance has reduced the average cure rate. This is also why metaanalyses have shown better results with second-generation proton pump inhibitors and with longer duration of therapy.29,30
Generally, we recommend omeprazole 40 mg twice a day or an equivalent (Tables 1–3).
Would a potassium-competitive acid blocker be better than a proton pump inhibitor?
Vonoprazan is a potassium-competitive acid blocker. It does not require intermediate complex formation and is stable at low pH. It has a longer half-life than proton pump inhibitors, and its bioavailability is unaffected by food.31 It was recently approved in Japan for H pylori eradication in combination with clarithromycin or metronidazole plus amoxicillin.18
Vonoprazan is more effective than current proton pump inhibitors for keeping the gastric pH high. There are no published studies of vonoprazan dual therapy in Western countries, but given twice a day for 7 days along with twice-daily amoxicillin it cured only approximately 80% of clarithromycin-resistant strains. Further studies are needed to identify the optimum proton pump inhibitor or potassium-competitive acid blocker, dose, and duration.
Misuse of antibiotics
In triple therapy, the second antimicrobial drug (eg, amoxicillin) is given in part to prevent resistance from developing. It is not clear whether the combination is additive or synergistic, but until we can reliably maintain the intragastric pH above 6.0, which would increase the effectiveness of the amoxicillin component of the regimen, this practice cannot be considered as misuse of antibiotics.
In contrast, in the 4-drug nonbismuth combinations (concomitant, sequential, and hybrid therapies) and the new vonoprazan, clarithromycin, and metronidazole triple therapies, 1 of the antibiotics provides no benefit to some, often most, of the patients.18–20,32 This practice should end when susceptibility data become more widely available and when vonoprazan becomes available, so that we can deliver effective vonoprazan-amoxicillin dual therapy.
First-, second-, and third-line therapies
Many recommendations give advice in terms of first-, second-, and third-line therapies. In practice, a physician should have at least 2 first-line regimens (a first and a second choice). Both should be proven highly successful as empiric therapies in one’s patient population but differ in terms of primary antibiotics. This approach allows the clinician to tailor therapy depending on whether he or she suspects antibiotic resistance (eg, if the patient has taken clarithromycin before) or the patient is allergic or cannot take 1 or more drugs.
Two treatment failures with 2 different regimens known to be effective suggest poor compliance (a difficult patient) or a multiple- drug-resistant infection (a difficult infection). That patient would require salvage therapy (Table 2), which logically should be based on antimicrobial testing or, at a minimum, consultation with someone who frequently deals with this problem.
Test of cure
Monitoring the outcome of therapy (testing for cure) is essential, as it provides a reliable measure of the local effectiveness of particular therapies and also serves as an early warning of development of resistance in one’s patient population.14
Unless there are compelling reasons, testing for cure should use noninvasive testing with the urea breath test or stool antigen test. It is recommended that this be delayed at least 4 weeks to allow the organisms if still present to repopulate the stomach sufficiently for the tests to become positive. Because antibiotics, bismuth, and proton pump inhibitors reduce the bacterial load, they should be withheld at least 2 weeks before testing. Histamine-2 receptor antagonists can be substituted for proton pump inhibitors if antisecretory therapy is needed for symptoms, and continued up to the day before testing. The urea breath test should contain citric acid to overcome any residual pH effects. Physician groups should share their experience so as to alert the community about which therapies should likely be avoided.33
Salvage therapy
Salvage therapy is given after 2 or more treatment failures with different antibiotics. Ideally, the regimen should be based on the results of antimicrobial testing. Current regimens include rifabutin triple therapy, dual therapy (a protein pump inhibitor or vonoprazan and amoxicillin), or furazolidone quadruple therapy (Table 2).
Furazolidone is a synthetic nitrofuran derivative that is effective against many enteric organisms, including gram-negative bacteria and protozoa. It is not available in most Western countries but is available in many other parts of the world.34,35 It is also a monoamine oxidase inhibitor and thus interacts with many drugs and foods (eg, soy sauce, aged cheeses), leading to a relatively high rate of side effects such as fever, palpitations, and skin rash.
Rifabutin-containing regimens, generally, a proton pump inhibitor, amoxicillin 1 g, and rifabutin 150 mg, all twice a day (Table 3) provide average cure rates of less than 80% (typically in the mid-70% range).36 Borody et al37 reported greater than 95% success with a 12-day regimen consisting of rifabutin 150 mg once daily (half-dose), amoxicillin 1.5 g 3 times a day, and pantoprazole 80 mg (approximately equivalent to omeprazole 20 mg) 3 times a day. Ciccaglione et al,38 in a small study, used a 10-day quadruple regimen containing a proton pump inhibitor, amoxicillin, rifabutin, and bismuth (all twice a day), with high cure rates. The results of these studies are yet to be confirmed, and the optimal rifabutin- containing regimen remains to be determined.
PROBIOTICS
There is considerable interest in using probiotics to enhance the effectiveness of antimicrobial therapy for H pylori by increasing tolerability, reducing side effects, and therefore improving compliance.39,40
In a meta-analysis of 14 randomized trials (N = 1,671), when probiotics were added, pooled H pylori eradication rates were only slightly improved: 83.6% (95% CI 80.5%–86.7%) with probiotics and 74.8% (95% CI 71.1%–78.5%) without probiotics by intent-to-treat analysis.41
Another meta-analysis of probiotics suggested that those containing Saccharomyces boulardii, Lactobacillus, and Bifidobacterium significantly increased the eradication rate of triple therapy in populations with high rates of antimicrobial resistance and reduced the risk of overall H pylori therapy-related adverse effects, especially diarrhea.42,43
Tables
How do you know if you need treatment?
The answer to that question is now difficult to answer. However, if you have GERD or SIBO, you probably want to undergo treatment.
Our blood test for H. pylori is going away starting October 2, 2023. If you are interested in this testing, you must get to a Labcorp collection facility with an order in hand before this date.
They have several justifications for removing this test, but the real one is disappearing reimbursement for the test.
They state that the antibodies stay elevated after the resolution of the infection. However, HOW DOES IT RESOLVE? ON IT'S OWN?
We have bone fide proof that treatment lowers the antibody level, and people who are successfully treated acknowledge improvement in gut-related issues (diarrhea, GERD, constipation, bloating, etc.) In addition, we often see an improvement in lab markers, especially the ESR measurement.
Note - the supplement program does not always lead to a reduction in the antibody levels. That is why we have four (4) levels of treatment suggestions.
Note - more expensive, less accurate, and inconvenient testing will still be available. The breath test and the stool test (yuck!).
Detecting and reducing (never eliminating) H. pylori is critical to health. It impacts your gut in many ways, making you susceptible to SARS-CoV-2 and other infections. You are what you ABSORB, and H. pylori impact absorption. It does this by reducing stomach acid and microbiome quantity and diversity.
What to do? Here are two options - If you are not testing, you are guessing, and ensuring H. pylori is minimized is THE critical first step to optimal repair and recovery processes.
Option 1: Get your H. pylori test before October 2, 2023. We will discuss this result during your next consult. We will not discuss the result with you at this time, but you will have the data. $40.00
Option 2: Same as option 1 above, but you can schedule a 15-minute consult to discuss the result and get action plans. $140.00
Contact Jodi jlaird@healthrevivalpartners.com
Evidence Labcorp is wrong, and this test is essential:
"The superior sensitivity and negative predictive value in our population support its use as a noninvasive test to rule out H pylori infection. Reflexive testing with positive serology followed by either stool antigen or urea breath test may optimize diagnostic accuracy in low-prevalence populations."
"Helicobacter pylori infection is common, with serologic prevalence exceeding 50% worldwide.1 However, there is considerable variation by location, for example, with prevalence of approximately 35% in the United States but as high as 88% in Nigeria.1 Within the United States, the prevalence of H pylori is related to geographic region and ethnicity, among other factors.1,2 Infection with H pylori is associated with gastric ulcers, adverse outcomes in bariatric surgery patients, and neoplasia including adenocarcinoma and gastric marginal zone lymphoma.3 Eradication is effective in preventing malignancy and can reverse nonneoplastic lesions.4-7"
"This study highlights the importance of ongoing assessment of H pylori laboratory test performance at the local and regional level. Selection and interpretation of H pylori testing should be informed by disease prevalence, potential for therapeutic interference, and cost, in addition to published analytical performance studies. Despite multiple guidelines recommending against its use, serology contributes substantially to accurate diagnosis of H pylori infection in our patient population."
Go to the publication link for references:
We are disheartened that this important test is going away. Absorption of nutrients is the single most important "dependent variable" with respect to your health.
You are how well you repair!
In the future, we will continue to recommend treatments for H. pylori. However, without this test, establishing effectiveness will become:
more expensive,
less convenient, and
less accurate
I encourage everyone - even those without obvious gut symptoms, to get this test before it is gone.
REFERENCES
1.↵Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015; 148:719–731.CrossRefPubMedGoogle Scholar
2.↵Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64:1353–1367.Abstract/FREE Full TextGoogle Scholar
3.↵Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther 2016; 14:577–585.Google Scholar
4.↵Leja M, Axon A, Brenner H. Epidemiology of Helicobacter pylori infection. Helicobacter 2016; 21(suppl 1):3–7.Google Scholar
5.↵Grossman MI. Closing remarks. Gastroenterology 1978; 74:487–488.Google Scholar
8.↵Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 2012; 61:646–664.Abstract/FREE Full TextGoogle Scholar
9.↵Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016; 151:51–69.CrossRefPubMedGoogle Scholar
6.↵IARC Helicobacter pylori Working Group. Volume 8. Helicobacter pylori eradication as a strategy for preventing gastric cancer. Lyon, France: International Agency for Research on Cancer, 2014.Google Scholar
7.↵Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893–2917.CrossRefPubMedGoogle Scholar
10.↵Graham DY, Dore MP. Helicobacter pylori therapy demystified. Helicobacter 2011; 16:343–345.CrossRefPubMedGoogle Scholar
11.↵Gatta L, Vakil N, Leandro G, Di MF, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and metaanalysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104:3069–3079.CrossRefPubMedGoogle Scholar
12.Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59:1143–1153.Abstract/FREE Full TextGoogle Scholar
13.↵Graham DY. Helicobacter pylori eradication therapy research: ethical issues and description of results. Clin Gastroenterol Hepatol 2010; 8:1032–1036.CrossRefPubMedGoogle Scholar
14.↵Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5:321–331.CrossRefPubMedGoogle Scholar
15.↵Hunt RH, Tytgat GNJGraham DY, Dore MP. Variability in the outcome of treatment of Helicobacter pylori infection: a critical analysis. In: Hunt RH, , Tytgat GNJ, editors. Helicobacter pylori Basic Mechanisms to Clinical Cure 1998. Dordrecht, Netherlands: Kluwer Academic Publishers, 1998:426–440.Google Scholar
16.↵Graham DY. Hp-normogram (normo-graham) for assessing the outcome of H. pylori therapy: effect of resistance, duration, and CYP2C19 genotype. Helicobacter 2015; 21:85–90.Google Scholar
17.↵Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12:177–186.CrossRefPubMedGoogle Scholar
18.↵Murakami K, Sakurai Y, Shiino M, Funao N, Nishmura A, Asaka M. Vono- prazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016; 65:1439–1446.Abstract/FREE Full TextGoogle Scholar
19.Graham DY. Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues. Gut 2016 Apr 7. pii: gutjnl-2016-311796. doi:10.1136/gutjnl-2016-311796. [Epub ahead of print].CrossRefGoogle Scholar
20.↵Matsumoto H, Shiotani A, Katsumata R, et al. Helicobacter pylori eradication with proton pump inhibitors or potassium-competitive acid blockers: the effect of clarithromycin resistance. Dig Dis Sci 2016; 61:3215–3220.Google Scholar
21.↵Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 2016; 65:870–878.Abstract/FREE Full TextGoogle Scholar
22.↵Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin North Am 2015; 44:537–563.CrossRefPubMedGoogle Scholar
23.↵Zhang W, Chen Q, Liang X, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 2015; 64:1715–1720.Abstract/FREE Full TextGoogle Scholar
24.↵Chen Q, Zhang X, Fu Q, et al. Rescue therapy for Helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline for bismuth quadruple therapy. Am J Gastroenterol 2016; 111:1736–1742.Google Scholar
25.↵Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998; 115:1272–1277.CrossRefPubMedGoogle Scholar
26.↵Marcus EA, Inatomi N, Nagami GT, et al. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment Pharmacol Ther 2012; 36:972–979.CrossRefPubMedGoogle Scholar
27.↵Sachs G, Shin JM, Munson K, et al. Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14:1383–1401.CrossRefPubMedGoogle Scholar
28.↵Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors: comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65:19–31.CrossRefPubMedGoogle Scholar
29.↵Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013;12:CD008337.PubMedGoogle Scholar
30.↵McNicholl AG, Linares PM, Nyssen OP, et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36:414–425.CrossRefPubMedGoogle Scholar
31.↵Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 2015; 6:e94.Google Scholar
32.↵Graham DY, Laine L. The Toronto Helicobacter pylori consensus in context. Gastroenterology 2016; 151:9–12.Google Scholar
33.↵Uotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test. Ann Transl Med 2015; 3:9.Google Scholar
34.↵Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 2013; 25:1134–1140.PubMedGoogle Scholar
35.↵Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol 2012; 8:1–2.Google Scholar
36.↵Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35:209–221.CrossRefPubMedGoogle Scholar
37.↵Borody TJ, Pang G, Wettstein AR, et al. Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23:481–488.CrossRefPubMedGoogle Scholar
38.↵Ciccaglione AF, Tavani R, Grossi L, et al. Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection: two pilot studies. Helicobacter 2016; 21:375–381.Google Scholar
39.↵Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol 2015; 21:10644–10653.Google Scholar
40.↵Zhang MM, Qian W, Qin YY, et al. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol 2015; 21:4345–4357.CrossRefPubMedGoogle Scholar
41.↵Tong JL, Ran ZH, Shen J, et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25:155–168.PubMedGoogle Scholar
42.↵Szajewska H, Setty M, Mrukowicz J, et al. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr 2006; 42:454–475.CrossRefPubMedGoogle Scholar
43.↵Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013; 47:25–32.CrossRefPubMedGoogle Scholar
Weekly Webinar Links: Join us for detailed health information - at no charge. All are welcome.
Monday at noon EST -
https://zoom.us/j/94642492535?pwd=c2IyOTRoQTdNQ3JhTFdlVXpPMGErUT09
Wednesday at 8 pm EST -
https://zoom.us/j/96863715606?pwd=VTRCNTQ1dEVoWnlRQjRkeGJYRXlSdz09
Be Bold - Be Brave - Stay Well
Comentarios